BioGaia has signed an agreement with Fleet Laboratories for the exclusive rights
to sell BioGaia's Probiotic tablets with strawberry flavour in the U.S. and its
territories (excluding Puerto Rico). Launch is planned to first quarter 2012.
Fleet will offer the probiotic tablets under its Pedia-Lax brand. Like BioGaia's
other digestive health probiotic products, the tablets contain L. reuteri
Protectis, a probiotic strain patented by BioGaia and one that has been involved
in numerous clinical studies on digestive and immune health. BioGaia already
works with C.B. Fleet's subsidiary Casen Fleet in Spain and Portugal, where
several of its probiotic dietary supplements are selling well.
BioGaia's products are available in pharmacies in about 60 countries worldwide.
In the U.S., in addition to the new deal with Fleet Laboratories, the BioGaia
brand line of products is distributed by Everidis Health Sciences and includes
BioGaia ProTectis Drops (for infants), BioGaia Probiotic Straws and BioGaia
Chewable Tablets (in the original lemon flavour).
- We are very pleased that the agreement with Fleet Laboratories will provide an
opportunity to broaden BioGaia's reach in the U.S., an important region with
strong growth potential, says Peter Rothschild, President of BioGaia.
About Fleet Laboratories
Founded in 1960 and headquartered in Lynchburg, VA. Fleet Laboratories is a
privately held manufacturer and marketer of products related to personal care
and health care. Formerly doing business under the name C.B. Fleet and well-
known for its line of laxative drug products, the company also markets a diverse
range of cosmetic and pharmaceutical products in 100 countries around the
world.
For additional information please contact:
Peter Rothschild, President, telephone: +46 8 555 293 00
BioGaia has published this information in accordance with the Swedish Securities
Market Act. The information was issued for publication on 18 August 2011, 3:00
pm CET.
BioGaia is a biotechnology company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri (Reuteri), which has probiotic,
health-enhancing effects.
The class B share of the Parent Company BioGaia AB is quoted on the Small Cap
list of the NASDAQ OMX Nordic Exchange Stockholm.
www.biogaia.com
[HUG#1539349]
